# Biodexa’s (NASDAQ:BDRX) Licensor Emtora’s Phase 2 Clinical Trial Results of FAP Treatment eRapa™ to Be Presented
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company with an emphasis on acquisitions, is eagerly announcing that Emtora Biosciences, its licensor, will present the results from their Phase 2 clinical trial on eRapa for the treatment of Familial Adenomatous Polyposis (FAP) at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC.
## About eRapa and The Phase 2 Clinical Trial
The oral tablet formulation of rapamycin, eRapa, is a proprietary product developed through the use of nanotechnology and pH-sensitive polymers. This formula is designed to overcome issues of poor bioavailability, variable pharmacokinetics and toxicity commonly associated with current forms of rapamycin. Emtora Biosciences holds exclusive rights to eRapa, and have issued patents protecting the product until 2035.
The Phase 2 clinical trial extended over a six month period, with Carol Burke, MD at the helm as Principal Investigator. The trial primarily focused on eRapa’s potential as a treatment for FAP, a disease characterized by the proliferation of polyps in the colon and/or rectum.
## FAP and the Potential of eRapa
FAP has a significant hereditary component, affecting patients typically in their mid-teens. The current standard of care revolves around active surveillance and surgical resection of the colon and/or rectum. With no approved treatment options for FAP patients, the potential of eRapa as a treatment option is significant.
There is also a strong rationale supporting the use of eRapa in FAP treatment. The active component of eRapa, rapamycin, works as an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR plays a crucial role in cellular metabolism, growth, and proliferation, all of which are activated during tumorgenesis. The mTOR pathway is known to be over-expressed in FAP polyps, hence the potential effectiveness of mTOR inhibitors like eRapa.
## Biodexa’s Collaboration with Emtora
Biodexa entered into a definitive agreement with Emtora for the rights to eRapa under an exclusive, worldwide license, enabling them to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa. The implications of this agreement could significantly shape the future for Biodexa and their role in addressing critical unmet medical needs.
Undoubtedly, biotech investors will have a keen eye on the Phase 2 clinical trial results due to be presented at the 2024 Digestive Disease Week annual meeting. As we watch Biodexa’s performance at the stock market, this biotech catalyst holds significant relevance for the company’s future valuation.